Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through multiple pharmacy platforms.

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence in the company's largest market.

As Novo Nordisk's share price drops, CEO Lars Fruergaard Jorgensen steps down. The company aims to maintain its lead in the competitive weight-loss drug market.

Numerous companies have unveiled investments in U.S. manufacturing in recent weeks, including TSMC, Eli Lilly, Hyundai Motor Group and others.

Made in the USA, a new daily oral weight-loss pill from Eli Lilly won't require cold storage and is expected to hit markets in 2026. It reportedly works as well as Ozempic.

Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the drug after liver issues affected one patient.

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

Telehealth company Ro has rolled out a new tool to track the supply of weight loss drugs like Ozempic and Wegovy across the U.S., as patients struggle with shortages.

Nestlé's new food line, Vital Pursuit, is specifically targeted toward patients using weight-loss medications, which continues to surge in popularity.

Novo Nordisk has been slowly increasing production capacity of its highly coveted weight loss drugs. As a result, thousands of people have began treatment per week.